Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | PLG | P00747 | 1/20 | 0.36 |
| ▸ | PLAT | P00750 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28428371 | 0.91 | CES2 (0.48) | KMT2AHDAC8HDAC6CES2CES1 | |
| SCHEMBL28424883 | 0.91 | CES2 (0.41) | KMT2ALMNAHDAC8HDAC6MEN1 | |
| SCHEMBL28422807 | 0.88 | CES2 (0.52) | HDAC8HDAC6CES2CES1HTT | |
| SCHEMBL11974546 | 0.87 | CES2 (0.50) | HDAC8HDAC6CES2CES1HSD17B10 | |
| SCHEMBL28426230 | 0.87 | CES2 (0.43) | KMT2AHDAC8HDAC6CES2CES1 | |
| SCHEMBL28425729 | 0.84 | CES2 (0.55) | HDAC8HDAC6CES2CES1HTT | |
| SCHEMBL28420726 | 0.84 | CES2 (0.48) | HDAC8HDAC6CES2CES1HSD17B10 | |
| SCHEMBL1549696 | 0.84 | — | — | |
| SCHEMBL29333109 | 0.84 | CES2 (0.55) | HDAC8HDAC6CES2CES1HTT | |
| SCHEMBL599277 | 0.84 | CES2 (0.55) | HDAC8HDAC6CES2CES1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | IAMBIC THERAPEUTICS, INC. | 2025-07-24 | — | — | US | disclosed |
| EP-4558502-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | Iambic Therapeutics, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20240034731-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. | 2024-02-01 | — | — | US | disclosed |
| WO-2024020419-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| EP-3707143-B9 | NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS | ONCOSTELLAE S L (ES) | 2023-04-12 | — | — | EP | disclosed |
| CN-111269097-B | Synthesis method of polycyclic disubstituted 1, 3-propanedione compound | 苏州爱玛特生物科技有限公司 | 2023-02-17 | — | — | CN | disclosed |
| EP-3707143-B1 | NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS | ONCOSTELLAE S L (ES) | 2022-12-28 | — | — | EP | disclosed |
| US-11453660-B2 | Androgen receptor and glucocorticoid receptor modulators | ONCOSTELLAE, S.L. | 2022-09-27 | — | — | US | disclosed |
| CN-115093323-A | Beta-functionalized chiral homoallyl alcohol derivative and preparation method and application thereof | 武汉大学 | 2022-09-23 | — | — | CN | disclosed |
| US-20200325123-A1 | NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS | ONCOSTELLAE, S.L. (ES) | 2020-10-15 | — | — | US | disclosed |
| EP-0986529-A1 | PROCESS FOR THE PREPARATION OF 1,3-DICARBONYL COMPOUNDS | EASTMAN CHEMICAL COMPANY (US) | 2000-03-22 | — | — | EP | disclosed |
| WO-1998055438-A1 | PROCESS FOR THE PREPARATION OF 1,3-DICARBONYL COMPOUNDS | EASTMAN CHEMICAL COMPANY (US) | 1998-12-10 | — | — | WO | disclosed |
| EP-0444899-B1 | Catechol derivatives, their physiologically acceptable salts, esters and their use in the treatment of tissue damage induced by lipid peroxidation | ORION YHTYMAE OY (FI) | 1997-02-05 | — | — | EP | disclosed |
| US-5489614-A | MEDICINAL ANTIOXIDANTS USED IN PREVENTION AND TREATMENT OF TISSUE DAMAGE INDUCED BY LIPID PEROXIDATION | ORION-YHTYMA OY (FI) | 1996-02-06 | — | — | US | disclosed |
| US-5292771-A | Treating inflammatory bowel disease | ORION-YHTYMA OY (FI) | 1994-03-08 | — | — | US | disclosed |
| US-5185370-A | Substituted β-diketones and their use | ORION-YHTYMA OY (FI) | 1993-02-09 | — | — | US | disclosed |
| EP-0444899-A2 | Catechol derivatives, their physiologically acceptable salts, esters and their use in the treatment of tissue damage induced by lipid peroxidation | ORION-YHTYMÀ OY (FI) | 1991-09-04 | — | — | EP | disclosed |
| EP-0440324-A2 | Substituted beta-diketones and their use | ORION-YHTYMÀ OY (FI) | 1991-08-07 | — | — | EP | disclosed |
| US-4224325-A | 3-(1-Pyrazolyl)-pyridazine derivatives and hypotensive compositions thereof | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1980-09-23 | — | — | US | disclosed |
| US-3966954-A | 3,5-Cycloalkyl pyrazolium salts as fungicides | AMERICAN CYANAMID COMPANY (US) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240034731-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | CCNI, CDKN1A, CDK8 | KMT2A 174/4885LMNA 2911/4885PLG 4347/4885 |
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | AZI2, TPMT, HDAC10 | KMT2A 709/4885LMNA 2164/4885PLG 4688/4885 |
| US-20200325123-A1 | NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS | NR5A1, AR, NR3C1 | KMT2A 4588/4885LMNA 3252/4885PLG 1389/4885 |
| US-11453660-B2 | Androgen receptor and glucocorticoid receptor modulators | AR, NR5A1, NR3C1 | KMT2A 4408/4885LMNA 3076/4885PLG 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.